INTRODUCTION
Upon binding to its receptor, insulin regulates numerous cellular responses including, for example, stimulation of glucose uptake, glycogen synthesis and lipogenesis in key target tissues such as skeletal muscle and white fat, whilst simultaneously suppressing hepatic gluconeogenesis. However, impaired insulin responsiveness (i.e. insulin resistance) of the above mentioned tissues leads to dysregulation in the hormonal control of these important physiological responses and contributes to the development of type 2 diabetes mellitus.
The mechanisms that contribute to the pathogenesis of insulin resistance are poorly understood but non-esterified fatty acids (NEFAs) have been implicated strongly in its development in tissues such as skeletal muscle [1, 2] . In particular, there is considerable evidence showing that increased circulating saturated fatty acids (SFAs) promote insulin resistance and reduce skeletal muscle glucose utilisation [3, 4] .
One potential mechanism that may help explain lipid-induced insulin resistance is the reciprocal relationship that exists with respect to skeletal muscle metabolism of glucose and fatty acids as proposed by Randle in the early 1960s [3] . The Randle hypothesis or the "glucose-fatty acid cycle", as it is also known, proposes that increased availability of free fatty acids to muscle would lead to elevated mitochondrial acetyl CoA/CoA and NADH/NAD ratios, which, in turn, would promote inhibition of pyruvate dehydrogenase, resulting in increased citrate levels and an attendant inhibition in phosphofructokinase activity. The effect of inhibiting this latter enzyme would be an overall reduction in glycolytic flux and accumulation of glucose-6-phosphate, which would inhibit hexokinase and thereby decrease glucose uptake. However, the finding that an increase in circulating fatty acids can impair glycogen synthesis in human muscle prior to any significant rise in intramuscular glucose-6-phosphate [4] implies the existence of additional regulatory mechanisms to the Randle cycle.
hormonal regulation of glucose transport and glycogen synthesis [6] . This inhibition appears to rely upon de novo synthesis of ceramide from palmitate, since inhibitors of serine palmitoyltransferase (SPT), the enzyme that commits palmitoyl-CoA to ceramide synthesis, antagonise the inhibitory effects of palmitate on PKB [5] . Indeed, short chain cell permeant analogues of ceramide mimic the inhibitory effect of palmitate on PKB activation and such studies have revealed that this inhibition, depending on the experimental system used, involves the ceramide-mediated activation of either a type 2A-like phosphatase, which dephosphorylates PKB on its regulatory phosphorylation sites, or of an atypical protein kinase C (PKC) isoform, which physically interacts with and negatively regulates PKB activation [7] [8] [9] [10] [11] [12] .
Intriguingly, while SFAs have been implicated in the development of insulin resistance, some mono-and poly-unsaturated fatty acids (MUFAs/PUFAs) appear to either have no adverse effects or positively enhance insulin action [13, 14] . Many studies carried out in whole animals have reported contradictory results with respect to the effects of MUFAs and PUFAs on insulin action. This inconsistency may, in part, be explained by the fact that dietary fat is often administered to animals as a mixture of several different fatty acids and there is good evidence that insulin sensitivity is influenced by the dietary fatty acid profile (for review see [15] ). However, distinct effects of individual saturated and unsaturated fatty acids have been documented in vitro on cell proliferation (for review see [16] ), and perhaps the best characterized example seems to be the ability of MUFAs to protect against β-cell apoptosis induced by SFAs [17] [18] [19] . In addition, oleate has been shown to stimulate basal glucose uptake in rat adipocytes, probably by mediating changes in the intrinsic activity of glucose transporters [20] . A previous attempt to characterise the effects of fatty acids in murine C2C12 myotubes focused mainly on the effect of SFAs on glycogen synthesis [21] , as these cells do not particularly serve as a good model for investigating GLUT4-mediated glucose uptake. Recent work from our laboratory has characterised the inhibitory effects of palmitate on insulin-stimulated glucose uptake in L6 myotubes [5] . In the present study we have investigated the effect of MUFAs (in particular the effect of palmitoleate) and PUFAs on insulin signaling and glucose metabolism. We show that, unlike SFAs, palmitoleate increases basal glucose uptake by Although the precise mechanism underlying this change in carrier abundance remains currently unknown, it appears that exposing muscle cells to palmitoleate results in enhanced glucose oxidation and glycogen synthesis and over-rides the inhibitory effect of palmitate on insulin-stimulated glucose uptake. , phospho-GSK3β−Ser 9 were from New England Biolabs (Hitchin, Herts, U.K.). Anti-GLUT1 antibody was purchased from Chemicon International (Hampshire, U.K.), anti-GLUT4 monoclonal antibody (clone 1F8) was obtained from Genzyme Diagnostics (Cambridge, MA, U.S.A.), the polyclonal antibody against the SNAT2 System A transporter was generated in house as described previously [22] , while a monoclonal antibody against the α1 subunit of the Na Glucose uptake was assayed by incubation with 10 µM 2-deoxy-
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(1 µCi/ml) for 10 min as described previously [23, 26] , while for amino acid transport activity cells were incubated for 10 min with 10µM [ Statistical analyses -Data analysis was performed using GraphPad Prism software and considered statistically significant at values of p<0.05. Bands from immunoblots were quantified using ImageJ software.
RESULTS
In an attempt to assess the effects of MUFAs (Fig 1) on basal glucose uptake, we initially performed time and dose response studies. Fig 1A shows that glucose uptake was progressively stimulated with increasing exposure time to 0.75 mM palmitoleate (16:1).
Maximal stimulation was achieved by 16 h as there were no significant increases in uptake beyond this incubation period. The increase in glucose uptake induced by the MUFA was also dose-dependent being maximally stimulated at palmitoleate concentrations of 0.75 mM (Fig 1B) . Given that in previous work we have shown that 0.75 mM palmitate (16:0) for 16 h induces a maximal suppression in the insulindependent regulation of key signaling intermediates such as PKB and GSK3 and that of glucose transport [5] , subsequent incubation of muscle cells with fatty acids were conducted for 16 h using 0.75 mM. The increase in glucose uptake was not restricted to palmitoleate, but was also observed in response to a 16 h incubation of L6 myotubes with equivalent concentrations of oleate (18:1), linoleate (18:2) and α-linoleneate (18:3) ( Fig   1C) . As shown in Fig 1D , insulin increased glucose uptake by ~50% and, in line with our previous work [5] , this hormonal stimulation was abolished when cells had been preincubated for 16 h with 0.75 mM palmitate. In contrast, irrespective of whether insulin was present or not, palmitate was unable to suppress the increase in glucose uptake elicited by palmitoleate ( Fig 1D) . It is noteworthy, that maximal concentrations of both insulin and palmitoleate did not seem to exert any additive effect, suggesting that both stimuli either activate the same post-receptor signaling molecules or that signals initiated by each stimulus may ultimately converge upon a common end-point that promotes an increase in hexose uptake (e.g. recruitment and/or activation of glucose transporters).
Since half maximal stimulation of glucose uptake with MUFAs was observed between 4-8 h of incubation with the fatty acid, it was important to establish whether there was significant fatty acid uptake into the cells during this period. As shown in Fig with a corresponding loss in fatty acid-associated radioactivity from the culture medium.
After 16 h, ~60% of the initial oleic acid presented remains in the culture media (Fig 2A) .
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Intriguingly, in parallel experiments, the impact of replacing the fatty acid containing medium every 4 h with fresh media supplemented with 0.75 mM oleate on glucose uptake was tested. This experimental manipulation led to a greater increase in glucose uptake (by ~50%) than that observed when the MUFA was not replenished in the incubation medium (Fig 2B) . This finding implies that by maintaining the fatty acid concentration in the medium by regular renewal of the culture medium is likely to enhance the intracellular accumulation of the fatty acid and thereby raise its effect on glucose uptake in this cell system.
Given the increase in glucose uptake elicited by palmitoleate we next examined the fate of glucose taken up by muscle cells by monitoring glucose oxidation and glycogen synthesis. Palmitoleate treatment of muscle cells increased glucose oxidation by ~50%
and was comparable to that seen in response to insulin, which was used as a positive control ( Fig 3A) . The MUFA also stimulated incorporation of glucose into glycogen by ~2-fold, but the increase was significantly lower than that induced by insulin (~4-fold, Fig 3B) . The ability of insulin to stimulate glycogen synthesis is associated with a significant phosphorylation (inactivation) of GSK3 and an associated dephosphorylation of glycogen synthase on Ser 641 and Ser 645 , two of the residues phosphorylated by GSK3
that play a critical role in regulating its activity. However, unlike insulin, palmitoleate did not promote GSK3 phosphorylation nor did it induce dephosphorylation of these GS residues ( Fig 3C) .
To assess the possibility that MUFAs may either activate molecules implicated in insulin signaling or antagonise the suppressive effect of SFAs on molecules mediating the insulin signal to processes regulating fuel use, we immunoblotted lysates from muscle cells following incubation with maximally effective concentrations of insulin, palmitate and/or palmitoleate with phospho-specific antibodies to PKB, GSK3 or p70S6K. Fig 4 shows that an acute (15 min) insulin incubation induced a robust phosphorylation of all three kinases (lane 2), but that cell treatment with palmitate or palmitoleate alone for 16 h (lanes 3 and 5, respectively) had no effect on the phosphorylation of these kinases.
However, when cells were incubated with palmitate for 16 h prior to an acute insulin . To assess whether the stimulatory effect of palmitoleate on glucose uptake involves activation of specific signaling pathways we investigated the effect of various inhibitors known to target the activation of select protein kinase cascades. Since it was not desirable to have these inhibitors present in the culture media for 16 h their ability to suppress the stimulatory effect of palmitoleate was monitored over 4 h, a period over which glucose uptake was stimulated significantly by the MUFA (Fig 1A) . It is important to stress that the efficacy of each of the inhibitors used was confirmed in parallel control experiments (data not shown). None of the inhibitors tested, with the exception of rapamycin, was able to suppress the increase in glucose uptake elicited by palmitoleate (Fig 5A) . Rapamycin caused a modest, but significant, reduction in the stimulation of glucose uptake by palmitoleate (the net increase in hexose uptake falling from 67% to 40% in the presence of the inhibitor). While this latter finding implies that mTOR may feature in the stimulatory action of palmitoleate, it is inconsistent with the lack of any stimulation in p70S6K (a downstream mTOR target) by the MUFA (Fig 4A, lane 5) . PKC isoforms have also been implicated in the action of certain free fatty acids, and so in separate To assess whether palmitoleate may have modified the cellular abundance or distribution of GLUT1 and GLUT4 we immunoblotted total cell membranes, as well as isolated plasma membranes from L6 cells following treatment with the MUFA. Consistent with the cycloheximide data shown in Fig 5A, we could not detect any increase in the total amounts of either GLUT1 or GLUT4 (Fig 7A) . However, analysis of plasma membranes isolated by subcellular fractionation revealed that the abundance of both transporters was noticeably elevated following palmitoleate treatment (Fig 7B, about 3 .5-fold for GLUT1 and 1.7-fold for GLUT4). In line with the well documented insulin-dependent translocation of both these transporters in this particular muscle cell line [23, 33, 34] , acute treatment of L6 myotubes with insulin induced a comparable increase in the cell surface abundance of both transporters (Fig 7A and 7B) . In separate experiments, exploring the effects of palmitate on palmitoleate-induced transporter recruitment, we could not detect any inhibitory effect of the SFA (data not shown) consistent with the uptake data shown in Fig 1D. It is also noteworthy that the ability of palmitoleate to induce an increase in cell surface GLUT1/GLUT4 content with an associated enhancement in glucose uptake does not form part of a generalized cell response to increase nutrient uptake. Like GLUT1 and GLUT4, the SNAT2 (System A) amino acid transporter is also recruited to the plasma membrane in response to insulin [24] , but unlike the glucose transporters it does not undergo an increase in cell surface abundance in response to palmitoleate ( Fig   8A and 8B ). This finding is fully consistent with the lack of any stimulation in functional System A transport over the 16 h incubation period with the MUFA (Fig 8C) . The abundance of the α1 subunit of the Na there is general acceptance that intake and deposition of saturated fat in particular, reduces the sensitivity of skeletal muscle to insulin [15] . Indeed, studies in rodents and human subjects have revealed that changing from a diet rich in SFA to one with a high proportion of monounsaturated fat improves glucose tolerance and insulin sensitivity led to a significant increase in basal glucose uptake. Some of the glucose taken up under these circumstances is oxidised, but a significant proportion is also channeled into synthesis of glycogen. Interestingly, the increase in glycogen synthesis induced by the MUFA is not dependent on dephosphorylation of GS on GSK3 target residues, which represent the principal sites of phosphate loss in response to insulin and which underpin the hormonal activation of GS [40] . Whilst we cannot exclude the possibility that activation of GS might be mediated by dephosphorylation of other sites, a more likely mechanism by which the enzyme is stimulated is via an increase in cytosolic glucose-6-phosphate [41] . The concentration of this allosteric activator of GS will increase as a direct consequence of the greater influx of glucose into cells exposed to the MUFA. The finding that insulin induces a much greater activation of glycogen synthesis than palmitoleate is fully in keeping with the fact that the hormone not only elevates glucose-6-phosphate via stimulation of glucose uptake, but will also simultaneously promote the dephosphorylation and thereby greater activation of GS.
We hypothesised that the increase in glucose uptake elicited by palmitoleate may involve activation of signaling molecules regulating glucose uptake in response to stimuli such as insulin and various stress-inducing agents [6, 27] . This possibility is supported by the observation that oleate, but not palmitate, activates PI3-kinase in human breast cancer cells and that this underlies the increase in cell proliferation induced by this MUFA [28].
However, our findings indicate that it is highly unlikely that palmitoleate stimulates PI3-kinase in L6 muscle cells given that the fatty acid does not activate PKB (a molecule whose activation is dependent on PIP3, a PI3-kinase reaction product) and its stimulatory Unlike insulin, which induces a rapid (within minutes) stimulation of glucose uptake, the increase observed in response to palmitoleate was slow and protracted suggesting that the effects of this MUFA may depend upon increased synthesis of glucose transporters.
However, this possibility is negated by the lack of any sensitivity to cycloheximide and the observation that there were no detectable changes in cellular GLUT1 or GLUT4 membrane. However, neither the work of Nugent et al. [44] nor pilot studies conducted in our laboratory were able to detect any significant changes in membrane fluidity (data not shown). Moreover, it is noteworthy, that unlike GLUT1 and GLUT4, the SNAT2 amino acid transporter, which is recruited to the plasma membrane in response to insulin [24] and whose insulin-stimulated activity is suppressed by palmitate [45], does not undergo changes in cell surface abundance or activity following cell treatment with palmitoleate.
These latter findings lend credence to the idea that the increase in glucose transport elicited by palmitoleate is unlikely to be part of a generalized response to the MUFA arising from non-specific effects on membrane fluidity. 
